Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Herceptin in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must be female.~* Informed consent must be signed.~* Women with locally advanced breast cancers or primary breast cancers with concomitant gross metastatic disease are eligible. Locally advanced cancers must be of clinical and/or radiologic size \> 4 cm, and/or are deemed surgically inoperable.~* Her2/neu overexpressing tumors defined as HercepTest score of 3+, or \>/= one-third of invasive tumor showing membranous staining, or fluorescence in situ hybridization (FISH) positive.~* Negative serum pregnancy test (bHCG) within 7 days of starting study, if of child-bearing potential.~* Kidney and liver function tests - all within 1.5 times of the institution's upper limit of normal.~* Performance status (World Health Organization \[WHO\] scale) \< 2 and life expectancy \> 6 months.~* Age \> 18.~* No metastatic disease without concomitant primary breast cancer.~* No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.~Exclusion Criteria:~* Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.~* Severe underlying chronic illness or disease.~* Cardiomyopathy or baseline left ventricular ejection fraction (LVEF) \< 50%.~* Patients on other investigational drugs while on study.~* Severe or uncontrolled hypertension defined as blood pressure (BP) \> 180/100 on three separate occasions.~* History of congestive heart failure.~* History of coronary arterial disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Heceptin (Type: EXPERIMENTAL): Herceptin administered to enrolled subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).